Summary: Propofol (2,6-diisopropylphenol) is administered intravenously for induction and maintenance of anesthesia; however, cases of progressive myocardial failure (propofol syndrome) related to the use of propofol have been reported. In the present study, the individual differences in pharmacokinetics and/or pharmacodynamics of propofol were investigated in patients who were genotyped for CYP2B6 and UGT1A9. Fifty-one patients treated with propofol in St. Marianna University Hospital were recruited for this study and provided written informed consent. The following parameters were analyzed: awakening time as a pharmacodynamic parameter, duration of propofol infusion, drug concentration in plasma after treatment, genotypes of CYP2B6 and UGT1A9, and age (4284 years, mean of 65 years). Propofol was rapidly cleared from the blood of the subjects as a result of distribution and elimination. The awakening time after stopping propofol infusion was significantly correlated with the duration of infusion and the maximum concentration of propofol in these subjects. The maximum plasma concentration of propofol after normalizing with the duration of infusion was affected by the CYP2B6 G516T variant (related to impaired function) and was significantly affected by a propofol risk index score that incorporated CYP2B6 G516T and UGT1A9 I399C>T (high expression) genotypes and advanced age. These results provide important information indicating that the genotypes of the two enzymes studied and advanced age are combinative determinant factors of the pharmacokinetics and/or pharmacodynamics of propofol.
Introduction
Propofol ¤2,6-diisopropylphenol, Diprivan¥ is intravenously administered for the induction or the maintenance of anesthesia. 1¥ The clinical merit of rapid and complete recovery that occurs even after relatively prolonged intravenous infusions of propofol 2¥ is attributable to extensive biotransformation of the parent compound, primarily by the liver. 1¥ However, a significant association has been reported between long-term and high-dose propofol infusion and the development of progressive myocardial failure ¤propofol syndrome¥. 3¥ Due to reduced clearance and consequent higher blood concentrations, a reduced and careful administration of propofol to elderly patients has been recommended ¤Diprivan package insert, AstraZeneca¥. It has been shown that the phase I and II metabolism of propofol involves hydroxylation followed by continuous glucuronidation and direct glucuronidation of propofol. 4®6¥ We reported that CYP2B6 plays an important role in propofol Ý-and 4-hydroxylation in human liver and that the hepatic contents of CYP2B6, CYP3A4, and CYP1A2 determine which P450 enzymes play major roles in propofol oxidation in individual patients. 7¥ Although there are several reports on propofol pharmacokinetics and drug interactions in humans, 7®14¥ the roles of individual drug-metabolizing enzymes in propofol pharmacokinetics in patients are still unknown.
In the present study, individual differences were investigated in the pharmacokinetics and/or pharmacodynamics of propofol in patients who were genotyped for the CYP2B6 and UGT1A9 genes. We report herein on propofol treatment ¤infusion time¥ and the metabolism of propofol. The effects of the two enzyme genotypes and age were analyzed as combinatory determinant factors of the pharmacokinetics and/or pharmacodynamics of propofol.
Materials and Methods
Subjects: Fifty-one patients treated with propofol ¤10 mg/mL propofol injectable emulsion, Diprivan¥ for surgical anesthesia in St. Marianna University Hospital were recruited for this study and provided written informed consent. The ethics committees of St. Marianna University and Showa Pharmaceutical University approved the study. The duration of propofol infusion and the awakening time from anesthesia ¤a sum time from stopping the infusion to eye opening, to spontaneous breathing, and to orientation¥ were recorded by trained anesthesiologists in St. Marianna University Hospital. The subjects comprised 28 men and 23 women ranging from 42 to 84 years of age ¤mean of 65 years, 29 subjects of h65 years¥; subjects were screened for plasma propofol levels for 60 min after infusion was stopped and were genotyped for CYP2B6 and UGT1A9. The doses of propofol were recorded ¤Table 1¥.
DNA analysis: Genomic DNA prepared from blood cells of the study participants was analyzed. It has been shown that the CYP2B6*6 allele is a useful biomarker for drug disposition, 15¥ and the intronic SNP UGT1A9 I399ChT is associated with increased UGT1A9 protein levels and increased glucuronidation activities toward propofol.
6¥
Because of the importance of 516 GhT in terms of enzyme expression, genotyping for CYP2B6 516 GhT ¤2B6*9 or 2B6*6¥ and 785 AhG ¤2B6*4 or 2B6*6¥ was conducted by subjecting polymerase chain reaction products to restriction enzyme digestion as described previously. 15¥ Because of the difficulty in identifying subjects with the frequent heterozygous CYP2B6 genotype ª516G/T; 785A/G«, CYP2B6 516 GhT was selected as a genetic marker for impaired CYP2B6 function instead of CYP2B6*6 in this study. UGT1A9 I399ChT ¤rs2741049¥ 6¥ was genotyped by direct sequencing 
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Determinant Factors for Propofol PK and PDon both strands using sequencing primers, 16¥ an ABI BigDye terminator cycle sequencing kit ¤Applied Biosystems, Foster City, CA, USA¥, and an ABI PRISM 3730xl DNA analyzer ¤Applied Biosystems¥.
Pharmacokinetic analysis: Propofol ¤h99%¥ was obtained from Sigma-Aldrich ¤St. Louis, MO, USA¥ as an analytical standard. 7¥ Plasma samples ¤100 µL¥ were treated by adding 400 µl of CH 3 OH. After vortex mixing, the tubes were centrifuged at 10,000 g for 10 min. An aliquot of the supernatant after filter treatment ¤Millex-LG, 0.20 µm, Millipore, Tokyo, Japan¥ was injected onto an analytical C 18 reversed-phase column ¤150 mm ' 4.6 mm, Capcell Pak C 18 UG120 S5, Shiseido, Tokyo, Japan¥ maintained at 30ôC. The mobile phase was 55% ¤v/v¥ acetonitrile at a flow rate of 0.6 ml/min. 17¥ The elution profiles of propofol were monitored fluorometrically at an excitation wavelength of 270 nm and an emission wavelength of 310 nm. Plasma concentrations of propofol were kinetically analyzed by Phoenix WinNonlin software version 6 ¤Pharsight, Mountain View, CA, USA¥ using a two-compartment analysis ¤Table 1¥.
Statistical analysis: The correlation analyses were carried out using statistical program Instat ¤GraphPad Software, San Diego, CA, USA¥. Analysis of variance was used to determine statistical significance ¤p g 0.05¥.
Results
Propofol was cleared from the blood of subjects as a result of distribution and elimination processes within 60 min after stopping the infusion ¤Table 1¥. Figure 1 shows the correlation between the duration of propofol infusion and the amount of propofol used, pharmacokinetic parameter values, and the awakening time in 51 subjects. As expected, the amount of propofol used was significantly correlated with the duration of infusion ¤r © 0.66, p g 0.001, Fig. 1A¥ . Maximum plasma concentrations of propofol just after stopping infusion ¤C 0 ¥ and the area under the curve for 60 min ¤AUC 0®60 ¥ showed large individual differences ¤Figs. 1B and 
1C¥
. The half-life calculated from drug concentrations at several points after stopping the infusion was correlated with the duration of propofol infusion ¤r © 0.46, p g 0.001, Fig. 1D¥ . Under these conditions, the observed awakening times of individuals were correlated with the duration of propofol infusion ¤r © 0.33, p g 0.05, Fig. 1E¥ . The awakening time after stopping propofol treatment showed large individual differences among the 51 subjects and was significantly correlated with the maximum concentrations of the parent drug in these subjects ¤r © 0.27, p g 0.05, Fig. 2A¥ . When the awakening time was normalized using the infusion duration time ¤as a marker of the amount of propofol used, Fig. 1A¥ , an increased correlation coefficient ¤r © 0.56, p g 0.0001¥ was obtained between the normalized awakening time and maximum plasma drug concentrations normalized using the duration of propofol infusion ¤Fig. 2B¥.
Because the maximum concentrations of propofol after infusion were found to be a marker for awakening times in the present study, the effects of variants in drugmetabolizing enzymes and the effects of age were analyzed ¤Fig. 3¥. When maximum concentrations normalized using the duration of propofol infusion were plotted against wildtype, heterozygote, and homozygote groups for the CYP2B6 G516T variant, apparently high concentrations were observed in the homozygote group with the CYP2B6 G516T variant ¤Fig. 3A¥. A similar tendency, but no statistical significance, was also seen for those with the UGT1A9 I399ChT variant ¤Fig. 3B¥. In addition, the awakening time normalized using the duration of infusion tended to increase with age ¤r © 0.22, p © 0.12¥. When the subjects were divided into two groups using the mean age of 65 years, a similar tendency, but no statistical significance, was seen in subjects aged over 65 years ¤data not shown¥.
A propofol risk index score that gives a maximum value of 3 for subjects with CYP2B6 G516T ¤impaired function¥ and UGT1A9 I399ChT ¤high expression¥ genotypes and advanced age is proposed in this study ¤Fig. 3C¥. Subjects carrying the CYP2B6 516 G/T or T/T genotype have 1 added to the proposed index score because of high plasma drug concentrations associated with CYP2B6*6. 18¥ Similarly, subjects carrying the UGT1A9 I399 C/T or C/C genotype have 1 added because of significantly high protein levels with UGT1A9 I399 T/T, 6¥ and those of an advanced age ¤over 65 years¥ also have 1 added. The maximum propofol concentrations normalized using the duration of infusion and the propofol risk index scores ¤from 0 to 3¥ were significantly associated by evaluation with one-way analysis of variance ¤p g 0.05¥. The post hoc test also indicated that the mean value of the maximum propofol concentrations normalized using the duration of infusion in the group with a score of 3 was significantly higher than that in the group with a score of 0 ¤p g 0.05¥.
Discussion
We previously reported that a rat P450 enzyme, presumably deactivated by propofol, had an important role in propofol metabolism in rats and that repeated intravenous administration of propofol could markedly decrease the biotransformation of propofol via P450 deactivation. 17¥ These findings in rats implied that chronic administration of propofol in humans could affect the pharmacokinetics of propofol itself and other coadministered drugs via P450 deactivation. Although the inactivation of P450 enzymes by propofol treatment has not been detected yet in our in vitro analyses with human liver enzymes, the elimination half-life of propofol from plasma in the present study with clinical patients treated with propofol was prolonged by increased propofol infusion time ¤Fig. 1D¥.
Because the maximum concentration of propofol after infusion ¤C 0 ¥ was found to be a good marker for awakening time ¤Fig. 2B¥, the effects of variants of drug-metabolizing enzymes and advanced age on the maximum concentrations of propofol were analyzed. Because of the difficulty in identifying subjects with the frequent heterozygous genotype CYP2B6 ª516G/T; 785A/G«, homozygous CYP2B6 516 GhT Fig. 3 . Relationships between C 0 normalized using the duration of propofol infusion and CYP2B6 G516T genotype (A), UGT1A9 I399ChT genotype (B), and the proposed propofol risk index, which includes CYP2B6 G516T and UGT1A9 I399ChT variants and age (C) In panel (C), when subjects carried the CYP2B6 516 G/T or T/T genotypes, 1 was added to the proposed index score, which was based on the reported warfarin-responsive index.
19) Similarly, when subjects carried UGT1A9 I399 T/C or C/C genotypes, 1 was added to the score, and if subjects were aged over 65 years, 1 was added to the score. The numbers in parentheses indicate the number of subjects in these groups. was selected as a genetic marker for impaired CYP2B6 function 18¥ instead of CYP2B6*6 in this study. Maximum concentrations of propofol normalized using the duration of infusion were apparently affected by the CYP2B6 G516T variant ¤related to imparted function, Fig. 3A¥ and were significantly affected by the propofol risk index scores, which combine the effects of CYP2B6 G516T and UGT1A9 I399ChT ¤high expression¥ genotypes and advanced age ¤Fig. 3C¥. Although in vitro findings suggested that the homozygote for intronic SNP UGT1A9 I399ChT is associated with increased UGT1A9 protein levels and increased glucuronidation activities toward propofol, 6¥ the effects of this variant were confirmed when the three factors were combined in the propofol risk index score ¤Fig. 3C¥ in the present study. A similar index system has been reported that uses the genotypes of two different genes, CYP2C9 and VKORC1, and classifies patients into three categories to give a warfarin-response index. 19¥ In 1999, the Ministry of Health and Welfare of Japan released notice no. 153 stating that 13 of 28 adverse reactions to propofol were observed in patients over 65 years old in the 3 years after approval of the drug in Japan. This notice is consistent with the incorporation of age over 65 years in the risk index for propofol in the present study. These findings and results imply that approximately 10% of patients treated with propofol in Japan have the highest risk index value of 3.
In conclusion, the present results provide important information for a deeper understanding of safe propofol treatment ¤in terms of infusion time¥ and the metabolism of propofol in vivo. Two enzyme genotypes and age were identified as determinant factors of the pharmacokinetics and/or pharmacodynamics of propofol in patients under surgical anesthesia.
